Tempus AI said Monday it has agreed to buy Personalis for $1.5 billion. Fremont, California-based Personalis makes a molecular residual disease test for cancer. Tempus expects the acquisition will ...
Multiple factors could get in the way of confirming a new commissioner before the midterm elections, experts said, leaving ...
An upcoming Medicare coverage decision for transcatheter aortic valve replacement devices and study readout for patients with ...
While Johnson & Johnson will go head to head with Intuitive in the U.S., analysts questioned whether its robotic surgery ...
The cyberattack follows Abbott’s recent $21 billion purchase of Exact Sciences. Abbott did not disclose what kind of ...
The computing platform will make its debut at the Society of Robotic Surgery meeting this week, as Medtronic challenges ...
The deal is the latest in a series of pacts that GE HealthCare has made with health systems, including with Sutter Health and ...
Shareholders approved a plan to dissolve the robot developer, at one time a well-financed contender to challenge surgical ...
Andrew Aberdale will help expand AiM’s strategic partnership ecosystem, including its recent collaboration with Siemens ...
Jorge Garces, who joined Abbott to oversee scientific strategy for cancer diagnostics after it acquired Exact Sciences, ...
The supply of the circuit boards needed to fix the devices is significantly constrained, preventing the company from ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results